Citation Impact
Citing Papers
Cancer immunotherapy beyond immune checkpoint inhibitors
2018
A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy
2022 StandoutNobel
Homoharringtonine and omacetaxine for myeloid hematological malignancies
2014
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects
2020 Standout
Development of therapeutic antibodies for the treatment of diseases
2020 Standout
CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments
2022
Can a Ketone Be More Reactive than an Aldehyde? Catalytic Asymmetric Synthesis of Substituted Tetrahydrofurans
2018 StandoutNobel
Homoharringtonine targets Smad3 and TGF-β pathway to inhibit the proliferation of acute myeloid leukemia cells
2017
Chimeric antigen receptor–modified T cells: CD19 and the road beyond
2018
Chimeric Antigen Receptor Therapy
2018 Standout
Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application
2018 Standout
Kann ein Keton reaktiver als ein Aldehyd sein? Katalytische asymmetrische Synthese von substituierten Tetrahydrofuranen
2018 StandoutNobel
Ionizable Lipid Nanoparticles with Integrated Immune Checkpoint Inhibition for mRNA CAR T Cell Engineering
2023 StandoutNobel
Synthesis of Optically Active Monoacid Side‐Chains of Cephalotaxus Alkaloids
2008
Works of Fangxia Wang being referenced
Combination chemotherapy with low‐dose cytarabine, homoharringtonine, and granulocyte colony‐stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia
2007
Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia
2010
Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma.
2017
Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma.
2017
[Efficiency of GHA priming therapy on patients with acute monocytic leukemia and its mechanism].
2010